Assessing the expression patterns of ICMs other than PD-L1, which can be targeted using ICIs, and tailoring treatment based on these expression patterns can potentially enhance the therapeutic outcomes in patients with CRC. The gene discussed is CD274; the disease is colorectal carcinoma.